Comparative analysis of pSpA* patients regarding HLA-B27 status (excluding PsA*)
| Total pSpA* (N=316) | HLA-B27+ (N=197) | HLA-B27− (N=119) | Univariate analysis | Multivariate analysis | ||||||
| N/mean | %/SD | N/mean | %/SD | N/mean | %/SD | OR | P value | OR | P value | |
| Men | 167 | 52.8 | 116 | 58.8 | 51 | 42.6 | 1.91 (1.21–3.04) | 0.006 | n.s.* | |
| Family history | 84 | 26.6 | 55 | 27.9 | 29 | 24.4 | 1.20 (0.72–2.04) | 0.489 | ||
| Age (year) | 42.9 | 14.6 | 40.4 | 13.7 | 47.0 | 15.2 | 0.97 (0.95–0.98) | <0.001 | n.s. | |
| Age onset (year) | 32.8 | 14.3 | 30.3 | 13.4 | 37.2 | 14.9 | 0.97 (0.95–0.98) | <0.001 | n.s. | |
| Age at diagnosis (year) | 36.8 | 14.9 | 33.5 | 14.1 | 42.3 | 14.7 | 0.96 (0.94–0.97) | <0.001 | 0.96 (0.94–0.98) | <0.001 |
| Diagnostic delay (month) | 4.0 | 6.3 | 3.3 | 6.1 | 5.1 | 6.5 | 0.96 (0.92–0.99) | 0.020 | n.s. | |
| Disease duration (year) | 10.1 | 9.2 | 10.2 | 9.7 | 9.8 | 8.2 | 1.01 (0.98–1.03) | 0.669 | ||
| Mono/oligoarticular pattern | 164/300 | 54.7 | 89/191 | 46.6 | 75/109 | 68.8 | 0.40 (0.24–0.64) | <0.001 | 0.48 (0.27–0.84) | <0.001 |
| Tarsitis | 46 | 14.6 | 34 | 17.3 | 12 | 10.1 | 1.86 (0.95–3.89) | 0.083 | n.s. | |
| Enthesitis | 172 | 54.4 | 113 | 57.4 | 59 | 49.6 | 1.37 (0.87–2.16) | 0.179 | ||
| Dactylitis | 69 | 21.8 | 42 | 21.3 | 27 | 22.7 | 0.92 (0.53–1.61) | 0.775 | ||
| Peripheral structural damage | 28 | 8.9 | 8 | 4.1 | 20 | 16.8 | 0.21 (0.08–0.48) | <0.001 | 0.31 (0.11–0.79) | 0.019 |
| Axial involvement | 180 | 57.0 | 129 | 65.5 | 51 | 42.9 | 2.53 (1.59–4.05) | <0.001 | n.s. | |
| Radiographic sacroilitis (AS* mNY* criteria fulfilment) | 98/298 | 32.9 | 71/184 | 38.6 | 27/114 | 23.7 | 3.52 (2.13–5.87) | <0.001 | n.s. | |
| Shoulder involvement | 69 | 21.8 | 53 | 26.9 | 16 | 13.4 | 2.4 (1.31–4.49) | 0.006 | 2.18 (1.06–4.71) | 0.039 |
| Hip involvement | 117 | 37.0 | 88 | 44.7 | 29 | 24.4 | 2.50 (1.53–4.19) | <0.001 | n.s. | |
| Uveitis | 58 | 18.4 | 51 | 25.9 | 7 | 5.9 | 5.58 (2.60–13.92) | <0.001 | 3.37 (1.48–8.72) | 0.006 |
| If uveitis, no of episodes | 6.4 | 8.6 | 7.1 | 9.0 | 1.9 | 1.5 | 1.13 (1.00–2.51) | 0.227 | ||
| IBD* | 14 | 4.4 | 3 | 1.5 | 11 | 9.2 | 0.15 (0.03–0.50) | 0.004 | n.s. | |
| Fibromyalgia | 30 | 9.5 | 9 | 4.6 | 21 | 17.6 | 0.22 (0.09–0.49) | <0.001 | 0.32 (0.12–0.81) | 0.020 |
AS, ankylosing spondylitis; IBD, inflammatory bowel disease; mNY, New York modified; n.s., not significant; PsA, Psoriatic Arthritis; pSpA, peripheral spondyloarthritis.